Table 3.
Comparison of adverse events between the two groups.
| Comparison of adverse drug reactions between the two groups (n, %) | ||||
|---|---|---|---|---|
| Adverse event | Pembrolizumab+chemotherapy (N=101) | Sintilimab+chemotherapy (N=63) | ||
| All grades | Grade III-IV | All grades | Grade III-IV | |
| Any terms | 91(90.1%) | 38(37.6%) | 58(92.1%) | 27(42.9%) |
| Alopecia | 45(44.6%) | 12(11.9%) | 32(50.8%) | 12(19.1%) |
| Anemia | 39(38.6%) | 8(7.9%) | 22(34.9%) | 7(11.1%) |
| White blood cell count decreased | 32(31.7%) | 12(11.9%) | 20(31.7%) | 8(12.7%) |
| Neutrophil count decreased | 31(30.7%) | 9(8.9%) | 19(30.2%) | 8(12.7%) |
| Platelet count decreased | 20(19.8%) | 5(5%) | 12(19%) | 3(4.8%) |
| Nausea | 36(35.6%) | 2(2%) | 21(33.3%) | 3(4.8%) |
| Vomiting | 9(8.9%) | 1(1%) | 8(12.7%) | 2(3.2%) |
| Decreased appetite | 24(23.8%) | 5(5%) | 18(28.6%) | 3(4.8%) |
| Constipation | 42(41.6%) | 3(3%) | 23(36.5%) | 3(4.8%) |
| Diarrhea | 9(8.9%) | 2(2%) | 8(12.7%) | 1(1.6%) |
| Transaminases increased | 21(20.8%) | 4(4%) | 16(25.4%) | 2(3.2%) |
| Fatigue | 30(29.7%) | 4(4%) | 18(28.6%) | 2(3.2%) |
| Peripheral neuropathy | 23(22.8%) | 5(5%) | 15(23.8%) | 3(4.8%) |
| Rash | 12(11.9%) | 2(2%) | 6(9.5%) | 2(3.2%) |
| Weight decreased | 20(19.8%) | 2(2%) | 10(15.9%) | 3(4.8%) |